Long-Term Safety and Efficacy of Guanfacine Extended Release in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder
- 1 June 2009
- journal article
- research article
- Published by Mary Ann Liebert Inc in Journal of Child and Adolescent Psychopharmacology
- Vol. 19 (3), 215-226
- https://doi.org/10.1089/cap.2008.0080
Abstract
Objective: Short-term, controlled studies of extended-release guanfacine (GXR), a selective α2A-adrenoreceptor agonist, demonstrate efficacy in treating attention-deficit/hyperactivity disorder (ADHD) symptoms as monotherapy. This 2-year open-label study was conducted to further assess the long-term safety and efficacy of GXR. Methods: Study participants, aged 6–17 years with ADHD, had previously been exposed to GXR therapy alone or in combination with psychostimulants in one of two antecedent trials. In this study, doses were titrated to 1, 2, 3, or 4 mg/day of GXR alone or in combination with a psychostimulant. Safety and efficacy data collected at clinic visits over 24 months provided further evidence of the overall safety and efficacy of GXR for treating ADHD. Results: The majority of adverse events (AEs) were mild to moderate, and few patients discontinued the study because of an AE. Efficacy measures demonstrated significant improvement beginning in the first month and lasting through the end of the 24-month treatment period. Throughout the entire 2-year study, 202 subjects (77.1%) discontinued and 60 (22.9%) completed the study. Conclusions: Overall, these data support that GXR monotherapy is generally safe and effective for treating ADHD.Keywords
This publication has 23 references indexed in Scilit:
- Clonidine for Attention-Deficit/Hyperactivity Disorder: II. ECG Changes and Adverse Events AnalysisJournal of the American Academy of Child & Adolescent Psychiatry, 2008
- A Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine Extended Release in Children and Adolescents With Attention-Deficit/Hyperactivity DisorderPEDIATRICS, 2008
- Combination pharmacotherapy for adult ADHDCurrent Psychiatry Reports, 2006
- Attention-deficit hyperactivity disorderThe Lancet, 2005
- Prevalence and Assessment of Attention-Deficit/Hyperactivity Disorder in Primary Care SettingsPEDIATRICS, 2001
- A Pilot Study of Methyiphenidate, Clonidine, or the Combination in ADHD Comorbid with Aggressive Oppositional Defiant or Conduct DisorderClinical Pediatrics, 2000
- A Meta-Analysis of Clonidine for Symptoms of Attention-Deficit Hyperactivity DisorderJournal of the American Academy of Child & Adolescent Psychiatry, 1999
- The Contribution of α2-Noradrenergic Mechanisms to Prefrontal Cortical Cognitive FunctionArchives of General Psychiatry, 1996
- Guanfacine Treatment of Comorbid Attention-Deficit Hyperactivity Disorder and Tourette's Syndrome: Preliminary Clinical ExperienceJournal of the American Academy of Child & Adolescent Psychiatry, 1995
- The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: evidence for alpha-2 receptor subtypesJournal of Neuroscience, 1988